OptiNose, Inc. (OPTN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OptiNose, Inc. (OPTN) trades at $9.60 with AI Score 47/100 (Grade C). OptiNose, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for ear, nose, and throat specialists. Market cap: $97.22M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for OPTN: OPTN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OPTN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OPTN: the 1 perspectives are evenly split.
How is this calculated? →OptiNose, Inc. (OPTN) Healthcare & Pipeline Overview
OptiNose, Inc. develops and commercializes specialty pharmaceuticals for ear, nose, and throat conditions, primarily focusing on treatments delivered via its proprietary exhalation delivery system (EDS). Their flagship product, XHANCE, addresses chronic rhinosinusitis with nasal polyps, positioning them in the specialty drug market.
What Is the Investment Thesis for OPTN?
OptiNose presents a focused investment opportunity within the specialty pharmaceutical sector, driven by its proprietary exhalation delivery system (EDS) technology. The company's primary revenue stream is currently XHANCE, indicated for chronic rhinosinusitis with nasal polyps. The ongoing Phase IIIb clinical trial for chronic sinusitis represents a potential catalyst for expansion into a broader patient population. Key risks include reliance on XHANCE sales, competition from existing treatments, and the success of future pipeline products like OPN-019. With a market capitalization of $97.22M and a gross margin of 91.0%, OptiNose's financial performance hinges on effective commercialization and successful clinical development. Investors should closely monitor XHANCE sales growth, clinical trial outcomes, and partnership developments.
Based on FMP financials and quantitative analysis
OPTN Key Highlights
- Market Cap of $97.22M indicates a small-cap company with potential for growth but also higher volatility.
- Gross Margin of 91.0% reflects strong pricing power and efficient manufacturing of XHANCE.
- Profit Margin of -55.6% highlights the company's current lack of profitability, requiring close monitoring of operating expenses and revenue growth.
- Beta of -0.89 suggests the stock is less volatile than the overall market, potentially offering some downside protection.
- No dividend yield reflects the company's focus on reinvesting earnings into growth initiatives.
Who Are OPTN's Competitors?
OPTN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPTN's Key Strengths?
- Proprietary exhalation delivery system (EDS) technology.
- Approved product (XHANCE) with established market presence.
- High gross margin (91.0%) indicates strong pricing power.
- Experienced management team focused on specialty pharmaceuticals.
What Are OPTN's Weaknesses?
- Reliance on a single product (XHANCE) for the majority of revenue.
- Negative profit margin (-55.6%) indicates a lack of profitability.
- Small market capitalization ($0.10 billion) increases vulnerability to market fluctuations.
- Limited geographic reach, primarily focused on the United States.
What Could Drive OPTN Stock Higher?
- Results from Phase IIIb clinical trial for XHANCE in chronic sinusitis expected in late 2026.
- Continued expansion of XHANCE sales through increased market penetration and awareness.
- Development and advancement of OPN-019 through clinical trials.
What Are the Key Risks for OPTN?
- Financial-distress signal — its Altman Z-Score of -8.93 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from existing and new treatments for nasal polyps and sinusitis.
- Regulatory setbacks or delays in the approval of pipeline products.
- Reliance on XHANCE sales for the majority of revenue.
- Negative profit margin and the need to raise additional capital.
What Are the Growth Opportunities for OPTN?
- Expansion of XHANCE Label: OptiNose has an opportunity to expand the label for XHANCE to include treatment for chronic sinusitis, currently in Phase IIIb clinical trials. Success in this trial and subsequent FDA approval could significantly increase the addressable patient population, potentially doubling XHANCE sales within 3-5 years. The market for chronic sinusitis treatments is estimated to be worth several billion dollars annually.
- OPN-019 Development and Commercialization: The development of OPN-019, combining a liquid EDS device with an antiseptic, presents a growth opportunity in addressing nasal and sinus infections. Successful clinical trials and regulatory approval could position OPN-019 as a novel treatment option, capturing a share of the anti-infective market within the ENT space. This could contribute significantly to revenue growth starting in 2028.
- Geographic Expansion: OptiNose could explore opportunities to expand its geographic reach beyond the United States. Partnering with international distributors or establishing a presence in key markets like Europe and Asia could drive revenue growth. The global market for nasal and sinus treatments is substantial, offering significant potential for expansion over the next 5-7 years.
- Strategic Partnerships and Licensing Agreements: OptiNose can leverage strategic partnerships and licensing agreements to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or licensing out its EDS technology could generate additional revenue streams and accelerate growth. These partnerships could materialize within the next 2-3 years.
- Further Development of EDS Technology: Continued innovation and development of the exhalation delivery system (EDS) technology can lead to new applications and improved drug delivery methods. This could create a competitive advantage and attract further investment and partnerships. Ongoing research and development efforts in this area are crucial for long-term growth and differentiation.
What Opportunities Does OPTN Have?
- Expansion of XHANCE label to include treatment for chronic sinusitis.
- Development and commercialization of OPN-019 for nasal and sinus infections.
- Geographic expansion into international markets.
- Strategic partnerships and licensing agreements to expand product portfolio.
What Threats Does OPTN Face?
- Competition from existing treatments for nasal polyps and sinusitis.
- Regulatory challenges and potential changes in reimbursement policies.
- Clinical trial failures for pipeline products.
- Product liability claims and potential recalls.
What Are OPTN's Competitive Advantages?
- Proprietary exhalation delivery system (EDS) technology provides a competitive advantage in drug delivery.
- Patents protect their key products and technologies, creating barriers to entry for competitors.
- Established relationships with ENT and allergy specialists facilitate product adoption and market penetration.
- Clinical data supporting the efficacy and safety of XHANCE strengthens its market position.
What Does OPTN Do?
Founded in 2000 and headquartered in Yardley, Pennsylvania, OptiNose, Inc. is a specialty pharmaceutical company dedicated to creating and marketing innovative solutions for patients treated by ear, nose, throat, and allergy specialists. The company's core technology revolves around its proprietary exhalation delivery system (EDS), designed to improve drug delivery to targeted areas within the nasal cavity. Their flagship product, XHANCE, utilizes the EDS to deliver a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. In addition to XHANCE, OptiNose has been developing OPN-019, which combines a liquid EDS device with an antiseptic. The company also has Onzetra Xsail, a powder EDS device, for which they have a license agreement with Currax Pharmaceuticals LLC for commercialization. Further expanding their research and development efforts, OptiNose has a license agreement with Inexia Limited to develop products containing orexin receptor agonists for various human diseases. OptiNose operates primarily in the United States, focusing on specialty markets within the pharmaceutical industry.
What Products and Services Does OPTN Offer?
- Develop and commercialize pharmaceutical products for ear, nose, and throat (ENT) conditions.
- Utilize their proprietary exhalation delivery system (EDS) to improve drug delivery to the nasal cavity.
- Offer XHANCE, a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps.
- Conduct clinical trials for new indications and formulations of their products.
- Partner with other companies for commercialization and development of their products.
- Focus on specialty markets within the pharmaceutical industry.
How Does OPTN Make Money?
- Develop and patent pharmaceutical products utilizing the exhalation delivery system (EDS).
- Commercialize products like XHANCE through direct sales and marketing efforts in the United States.
- Generate revenue through product sales to pharmacies, hospitals, and healthcare providers.
- License out technology and products to other companies for commercialization in specific territories or applications.
What Industry Does OPTN Operate In?
OptiNose operates within the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for chronic rhinosinusitis treatments is growing, driven by increasing prevalence and awareness of the condition. OptiNose differentiates itself through its proprietary exhalation delivery system (EDS), which aims to improve drug delivery and efficacy compared to traditional nasal sprays. Key competitors include companies offering alternative treatments for nasal polyps and sinusitis. The overall pharmaceutical market is subject to pricing pressures and regulatory changes, which can impact OptiNose's profitability and growth prospects.
Who Are OPTN's Key Customers?
- Ear, nose, and throat (ENT) specialists.
- Allergy specialists.
- Patients suffering from chronic rhinosinusitis with nasal polyps.
- Pharmacies and hospitals that stock and dispense OptiNose products.
How OptiNose, Inc. Is Valued
OptiNose, Inc. carries a market capitalization of $97.22M, placing it in the micro-cap category. Relative to its peer group, OPTN's quantitative score of 47/100 is below the peer average of 66/100.
Company Profile
OptiNose, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Yardley, US. The company is led by CEO Ramy A. Mahmoud. OPTN has traded publicly since 2017.
ROE 45%Key Financial Metrics
Return on equity for OptiNose, Inc. stands at 44.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -19.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.64 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -20.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
OptiNose, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.93 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project OptiNose, Inc. revenue of about $113.6M for fiscal 2026, with EPS near $-0.97.
OPTN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in a turnaround.
- Community sentiment has shifted positively, with discussions highlighting potential growth opportunities in emerging markets.
- Analysts have noted improvements in operational efficiency, which could lead to better profit margins moving forward.
- The company has been actively engaging with investors, fostering a sense of transparency and trust that often boosts market perception.
Bear Case
- Concerns over recent earnings reports have led to skepticism about the company's ability to meet growth expectations.
- Social media sentiment includes a notable number of bearish opinions, reflecting doubts about the company's long-term viability.
- Market perception has been impacted by broader economic uncertainties, causing hesitation among investors regarding new positions.
- There have been reports of increased competition in the sector, raising questions about OPTN's market share and pricing power.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
OPTN Latest News
No recent news available for OPTN.
OPTN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPTN.
Price Targets
Wall Street price target analysis for OPTN.
OPTN MoonshotScore
What does this score mean?
The MoonshotScore rates OPTN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ramy A. Mahmoud
CEO
Ramy A. Mahmoud serves as the CEO of OptiNose, Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and strategic development. Prior to joining OptiNose, he held leadership positions at other pharmaceutical companies, contributing to the launch and growth of various products. His expertise spans across various therapeutic areas, including respiratory and allergy. He brings a strong understanding of the specialty pharmaceutical market and a track record of driving growth and innovation.
Track Record: Under Ramy A. Mahmoud's leadership, OptiNose has focused on expanding the market reach of XHANCE and advancing the development of its pipeline products. Key achievements include the ongoing Phase IIIb clinical trial for chronic sinusitis and the continued development of OPN-019. His strategic decisions have aimed at maximizing the value of the company's proprietary EDS technology and building a sustainable business model.
OptiNose, Inc. Healthcare Stock: Key Questions Answered
What does OptiNose, Inc. do?
OptiNose, Inc. is a specialty pharmaceutical company that develops and commercializes products for patients treated by ear, nose, and throat (ENT) and allergy specialists. Their primary focus is on utilizing their proprietary exhalation delivery system (EDS) to improve the delivery of medications to the nasal cavity. Their flagship product, XHANCE, is used to treat chronic rhinosinusitis with nasal polyps, offering a targeted and effective treatment option. The company is also developing other products using the EDS technology to address various ENT-related conditions.
What do analysts say about OPTN stock?
Analyst coverage of OptiNose, Inc. (OPTN) typically focuses on the potential of XHANCE and the company's pipeline products. Key valuation metrics include revenue growth, gross margin, and cash burn rate. Considerations for growth include successful clinical trial outcomes, market penetration of XHANCE, and potential partnerships. Analyst consensus generally reflects a cautious optimism, contingent on the company's ability to execute its commercial strategy and advance its pipeline. However, no specific buy or sell recommendations are made here.
What are the main risks for OPTN?
The main risks for OptiNose, Inc. include reliance on XHANCE sales, competition from existing and new treatments for nasal polyps and sinusitis, regulatory challenges and potential delays in the approval of pipeline products, and the need to raise additional capital. Clinical trial failures for pipeline products could also negatively impact the company's prospects. Additionally, product liability claims and potential recalls pose risks to the company's reputation and financial performance. These risks are inherent in the pharmaceutical industry and require careful monitoring.
What are the key factors to evaluate for OPTN?
OptiNose, Inc. (OPTN) holds an AI score of 47/100 (low). Not financial advice.
How frequently does OPTN data refresh on this page?
OPTN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OPTN's recent stock price performance?
OptiNose, Inc. (OPTN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary exhalation delivery system (EDS) technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPTN overvalued or undervalued right now?
Valuing OptiNose, Inc. (OPTN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OPTN?
Before investing in OptiNose, Inc. (OPTN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent filings.